---
title: 非危重成人平衡晶体与生理盐水的比较
date: 2022-04-16 07:27:34
permalink: /pages/22fc14/
categories:
  - 重症文献
tags:
  - 
---
# 非危重成人平衡晶体与生理盐水的比较

Wesley H. Self, M.D., M.P.H., Matthew W. Semler, M.D., Jonathan P. Wanderer,  M.D., Li Wang, M.S., Daniel W. Byrne, M.S., Sean P. Collins, M.D., Corey M.  Slovis, M.D., Christopher J. Lindsell, Ph.D., Jesse M. Ehrenfeld, M.D., M.P.H.,  Edward D. Siew, M.D., Andrew D. Shaw, M.B., Gordon R. Bernard, M.D., and Todd W.  Rice, M.D., for the SALT-ED Investigators*

N Engl J Med 2018;378:819-28.
DOI: 10.1056/NEJMoa1711586

## 摘要

**背景** 平衡晶体液和生理盐水的临床疗效比较尚不确定，特别是那些无需住ICU的非危重病人。

**方法** 我们进行了一项单中心、实用的、多重交叉试验，对急诊科静脉输注晶体液治疗并随后在除ICU以外的科室住院的成年人应用平衡晶体液(乳酸林格或勃脉力)和生理盐水进行比较。在为期16个月的试验中，急诊科给每个患者使用的晶体液种类以日历上的月为基础，平衡晶体液和生理盐水在整个急诊科按月交替使用。主要结果是非住院天数(出院后第28天前的存活天数)。次要结果为30天内的主要肾脏不良事件（包括全因死亡、新开始的肾脏替代治疗或持续性肾功能障碍(定义为肌酐水平上升至 ≥200% 的基线值)，所有调查都在出院时或30天内进行，以先发生者为准。

**结果 **共有13347例患者入选，急诊应用晶体液的中位数为1079 ml，88.3%的患者只接受了规定的晶体液。平衡晶体液组和生理盐水组的非住院天数没有差异(中位数，每组25天；平衡晶体液调整后的优势比为0.98；95%可信区间[CI]为0.92至1.04；P=0.41)。平衡晶体液在30天内的主要肾脏不良事件发生率低于生理盐水(4.7%对5.6%；调整后优势比为0.82；95%可信区间为0.70至0.95；P=0.01)。

**结论** 在急诊科静脉输液治疗的非危重成人中，平衡晶体液治疗和生理盐水治疗的非住院天数没有差异。





**Balanced Crystalloids versus Saline in Noncritically Ill Adults**

## Abstract

**BACKGROUND** Comparative clinical effects of balanced crystalloids and saline  are uncertain, particularly in noncritically ill patients cared for outside an  intensive care unit (ICU). 

**METHODS** We conducted a single-center,  pragmatic, multiple-crossover trial comparing balanced crystalloids (lactated  Ringer’s solution or Plasma-Lyte A) with saline among adults who were treated  with intravenous crystalloids in the emergency department and were subsequently  hospitalized outside an ICU. The type of crystalloid that was administered in  the emergency department was assigned to each patient on the basis of calendar  month, with the entire emergency department crossing over between balanced  crystalloids and saline monthly during the 16-month trial. The primary outcome  was hospital-free days (days alive after discharge before day 28). Secondary  outcomes included major adverse kidney events within 30 days — a composite of  death from any cause, new renal-replacement therapy, or persistent renal  dysfunction (defined as an elevation of the creatinine level to ≥200% of  baseline) — all censored at hospital discharge or 30 days, whichever occurred  first. 

**RESULTS** A total of 13,347 patients were enrolled, with a median  crystalloid volume administered in the emergency department of 1079 ml and 88.3%  of the patients exclusively receiving the assigned crystalloid. The number of  hospital-free days did not differ between the balanced-crystalloids and saline  groups (median, 25 days in each group; adjusted odds ratio with balanced  crystalloids, 0.98; 95% confidence interval [CI], 0.92 to 1.04; P = 0.41).  Balanced crystalloids resulted in a lower incidence of major adverse kidney  events within 30 days than saline (4.7% vs. 5.6%; adjusted odds ratio, 0.82; 95%  CI, 0.70 to 0.95; P = 0.01). 

**CONCLUSIONS** Among noncritically ill adults  treated with intravenous fluids in the emergency department, there was no  difference in hospital-free days between treatment with balanced crystalloids  and treatment with saline.



![NEJM医学前沿](/img/upload/202110311730698.png)

参考：NEJM 医学前沿的译文

[在非危重成人患者中应用平衡晶体液或生理盐水的比较](https://nejmqianyan.cn/article/yxqyoa1711584?sg=AbW1NGsHw3NxPd6F)
